financetom
Business
financetom
/
Business
/
Samsara Insider Sold Shares Worth $5,444,692, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Samsara Insider Sold Shares Worth $5,444,692, According to a Recent SEC Filing
Jan 13, 2025 2:33 PM

05:03 PM EST, 01/13/2025 (MT Newswires) -- John Bicket, 10% Owner, Director, Executive Vice President, Chief Technology Officer, on January 08, 2025, sold 124,822 shares in Samsara (IOT) for $5,444,692. Following the Form 4 filing with the SEC, Bicket has control over a total of 1,933,195 shares of the company, with 302,255 shares held directly and 1,630,940 controlled indirectly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1642896/000141588925001389/xslF345X05/form4-01132025_090141.xml

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Oncolytics Biotech CEO Matt Coffey to Take Medical Leave of Absence
Oncolytics Biotech CEO Matt Coffey to Take Medical Leave of Absence
Jun 24, 2024
08:11 AM EDT, 06/24/2024 (MT Newswires) -- Oncolytics Biotech ( ONCY ) said Monday that Chief Executive Officer Matt Coffey will take a medical leave of absence, effective immediately. Wayne Pisano, chair of Oncolytics' board of directors since 2013, will serve as interim CEO during his absence. Price: 0.9900, Change: -0.02, Percent Change: -1.98 ...
Adicet Bio Receives FDA Clearance for ADI-270 New Drug Application
Adicet Bio Receives FDA Clearance for ADI-270 New Drug Application
Jun 24, 2024
08:15 AM EDT, 06/24/2024 (MT Newswires) -- Adicet Bio ( ACET ) said Monday the US Food and Drug Administration has cleared its investigational new drug application for its ADI-270 cancer therapy. The company said it plans to start a phase 1 trial to assess the safety and anti-tumor activity of ADI-270 in relapsed/refractory renal cell carcinoma patients in H2....
Regulus Therapeutics Says Potential Kidney Disease Drug Well-Tolerated in Phase 1b Study
Regulus Therapeutics Says Potential Kidney Disease Drug Well-Tolerated in Phase 1b Study
Jun 24, 2024
08:15 AM EDT, 06/24/2024 (MT Newswires) -- Regulus Therapeutics ( RGLS ) said Monday that results from the third cohort of patients in its phase 1b study showed that its investigational drug RGLS8429 was well-tolerated with no safety concerns. The investigational drug is being evaluated in adults with autosomal dominant polycystic kidney disease, or ADPKD. Enrolment is ongoing for the...
Ripple effect from CDK hack widens as more US auto dealers flag hit
Ripple effect from CDK hack widens as more US auto dealers flag hit
Jun 24, 2024
June 24 (Reuters) - More U.S. auto dealers flagged a hit from an outage of CDK's software system due to a cyber attack on Monday as the company worked to restore systems used by over 15,000 retail locations across North America. AutoNation ( AN ), a leading auto retailer in the U.S. said the outage was disruptive and had adversely...
Copyright 2023-2026 - www.financetom.com All Rights Reserved